Skip to main content
. Author manuscript; available in PMC: 2021 Mar 4.
Published in final edited form as: ACS Appl Bio Mater. 2020 Mar 16;3(5):2838–2849. doi: 10.1021/acsabm.0c00101

Figure 3.

Figure 3.

Schematic depiction of mRNA vaccines for cancer immunotherapy.86 Note that, by using MHC-I or MHC-II-restricted antigens that are translated from mRNA vaccines, both arms of CD8+ and CD4+ T cell responses, respectively, can be elicited or augmented. Adapted with permission from ref 86. Copyright (2013) Elsevier Publishing Group.